Boden..
AEterna Zentaris Inc. (NASDAQ:AEZS) remains a strong buy in the latest set of rankings. The shares has received an average rating of 1 by 2 analysts. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company. AEterna Zentaris Inc. (NASDAQ:AEZS): 2 Analyst have given the stock of AEterna Zentaris Inc. (NASDAQ:AEZS) a near short term price target of $1.63. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.53. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.
The company shares have dropped 75% in the past 52 Weeks. On September 2, 2014 The shares registered one year high of $1.54 and one year low was seen on May 27, 2015 at $0.26. The 50-day moving average is $0.36 and the 200 day moving average is recorded at $0.53. S&P 500 has rallied 7.51% during the last 52-weeks.
AEterna Zentaris Inc. (NASDAQ:AEZS) witnessed a decline in the market cap on Monday as its shares dropped 1.1% or 0.0031 points. After the session commenced at $0.2831, the stock reached the higher end at $0.2831 while it hit a low of $0.273. With the volume soaring to 3,213,482 shares, the last trade was called at $0.2799. The company has a 52-week high of $1.54. The company has a market cap of $27 million and there are 95,895,000 shares in outstanding. The 52-week low of the share price is $0.2613.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Companys pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.
www.insidertradingreport.org/...entaris-inc-nasdaqaezs/618548/